Methodological Issues in Clinical Drug Development for Essential Tremor

oleh: Michael A. Carranza, Madeline R. Snyder, Rodger J. Elble, Angelique E. Boutzoukas, Theresa A. Zesiewicz

Format: Article
Diterbitkan: Ubiquity Press 2012-08-01

Deskripsi

<div id="ojsAbstract"><p>Essential tremor (ET) is one of the most common tremor disorders in the world. Despite this, only two medications have received Level A recommendations from the American Academy of Neurology to treat it (primidone and propranolol). Even though these medications provide relief to a large group of ET patients, up to 50% of patients are non-responders. Additional medications to treat ET are needed. This review discusses some of the methodological issues that should be addressed for quality clinical drug development in ET.</p></div><p><strong><br /></strong></p>